Pheast Therapeutics has dosed the first patient in the Phase 1b combination portion of its ongoing Phase 1 study of PHST001 (NCT06840886), an IgG4 anti-CD24 macrophage checkpoint inhibitor. Initial expansion cohorts are enrolling patients with advanced ovarian cancer, endometrial cancer, and cholangiocarcinoma. The company plans to share preliminary clinical and translational findings from the Phase 1a monotherapy escalation, along with two preclinical combination studies, at AACR 2026. PHST001 holds FDA Fast Track designation for ovarian cancer.
The move into chemotherapy combinations signals that early safety and pharmacodynamic readouts in monotherapy have been sufficient to justify testing PHST001 alongside standard backbones. Targeting the CD24–Siglec‑10 axis aims to enhance macrophage-mediated phagocytosis, a differentiated innate immune approach relative to the more mature CD47 class. Positioning PHST001 as an IgG4 may reduce Fc-effector activity and mitigate on-target hematologic liabilities that have complicated development of other myeloid checkpoint agents. The selected tumor types are pragmatic: high CD24 expression is common, the standard regimens are well characterized, and current immunotherapy options have delivered inconsistent benefits, leaving room for additive activity.
Strategically, Pheast is leaning into a combination-first path to surface a clearer efficacy signal in hard-to-treat settings while maintaining monotherapy escalation to define the upper bound of tolerability. This dual track can compress timelines to a go/no-go decision on expansion cohorts and future randomized studies, particularly in ovarian cancer where Fast Track could enable earlier regulatory engagement. The company is also seeding the scientific narrative ahead of AACR, where even a handful of confirmed responses or coherent pharmacodynamic evidence of macrophage activation could catalyze interest and site momentum.
For sites and CROs, Phase 1b will bring the usual operational friction of combination dose finding: overlapping myelosuppression with platinum- and taxane-based regimens in gynecologic cancers, and gemcitabine/cisplatin in cholangiocarcinoma, will complicate attribution and DLT adjudication. Expect translationally dense protocols with serial bloods and optional or mandated biopsies to measure CD24 expression, Siglec‑10 engagement, macrophage infiltration, and phagocytosis markers. If biomarker enrichment is contemplated after AACR, central assay standardization for CD24 by IHC or other modalities will become a gating factor for broader site participation. Imaging cadence and RECIST rigor will matter if Pheast pursues early randomized signals or regulatory conversations around accelerated pathways.
Regulators will focus on hematologic safety, infection risk, and additive toxicities when PHST001 is layered on top of chemo, as well as the internal consistency between pharmacokinetics, receptor occupancy, and downstream immune activation. For vendors, this program favors partners with innate immunity analytics, robust bioanalysis for IgG4 therapeutics, and scalable central pathology. Ovarian and endometrial networks could accelerate enrollment; cholangiocarcinoma will test referral pathways and geographic spread.
Near term, the AACR readout should clarify the dose selected for combination cohorts, any early activity in platinum-exposed ovarian patients, and whether a biomarker-response relationship can be articulated. Watch for the cytokine and infusion reaction profile, durability of disease control beyond two cycles, and hematologic signals distinguishable from background chemotherapy. Competitive context also matters: CD47 programs remain in flux, leaving space for CD24 if it demonstrates cleaner safety and combinability, but cross-talk across innate checkpoints could push Pheast toward triplets with PD‑(L)1 or other myeloid modulators, adding complexity and cost.
Key risks include heterogeneous CD24 expression across and within tumors, uncertain translatability of preclinical macrophage activation to human responses, and the operational burden of combination-first dose finding. If AACR provides credible preliminary efficacy and a coherent biomarker story, expect Pheast to prioritize a gynecologic lead, consider randomized expansion against chemotherapy, and engage regulators on the contours of a potential expedited path.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
